Evidence map›Paper›PMID 29410964›Full record

ArticleBioMed research international2017

A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis.

Chiaki Murakami, Nami Kakuta, Katsuyoshi Kume, Yoko Sakai, Asuka Kasai, Takuro Oyama, Katsuya Tanaka, Yasuo M Tsutsumi

Registry-linked trialOpen access · hybridAbstract readComparative Study
In one paragraph

Article in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05881486 (The Effects of Intravenous Fosaprepitant and Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Thoracicsurgery Patients), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05881486 naunknown statusnot on this mapstarted 2023, after this paper: background citation

The Effects of Intravenous Fosaprepitant and Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Thoracicsurgery Patients: A Single-center, Randomized, Double-Blinded Clinical Study

TypeinterventionalSponsorQilu Hospital of Shandong UniversityRan2023 to 2023Enrolled234ConditionsPostoperative Nausea and Vomiting, Anesthesia Complication, Thoracic DiseasesArmsOndansetron 8mg, Fosaprepitant 150 mg
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chiaki MurakamiDepartment of Anesthesiology, Tokushima University, 3-18-15 Kuramoto, Tokushima 770-8503, Japan.
Nami KakutaDepartment of Anesthesiology, Tokushima University, 3-18-15 Kuramoto, Tokushima 770-8503, Japan.ORCID 0000-0003-0453-1506
Katsuyoshi KumeDepartment of Anesthesiology, Tokushima University, 3-18-15 Kuramoto, Tokushima 770-8503, Japan.
Yoko SakaiDepartment of Anesthesiology, Tokushima University, 3-18-15 Kuramoto, Tokushima 770-8503, Japan.
Asuka KasaiDepartment of Anesthesiology, Tokushima University, 3-18-15 Kuramoto, Tokushima 770-8503, Japan.
Takuro OyamaDepartment of Anesthesiology, Tokushima University, 3-18-15 Kuramoto, Tokushima 770-8503, Japan.
Katsuya TanakaDepartment of Anesthesiology, Tokushima University, 3-18-15 Kuramoto, Tokushima 770-8503, Japan.
Yasuo M TsutsumiDepartment of Anesthesiology, Tokushima University, 3-18-15 Kuramoto, Tokushima 770-8503, Japan.ORCID 0000-0002-1997-082X
Tokushima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Postoperative nausea and vomiting (PONV) occur in 30-50% of patients undergoing general anesthesia and in 70-80% of high PONV risk patients. In this study, we investigated the efficacy of fosaprepitant, a neurokinin-1 (NK1) receptor antagonist, compared to ondansetron, a selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, in moderate to high PONV risk patients from our previous randomized controlled trials. Patients (171 patients from 4 pooled studies) with the Apfel simplified score ≥ 2 and undergoing general anesthesia were randomly allocated to receive intravenous fosaprepitant 150 mg (NK1 group,

Indexed as

Databases as TopicAdultAgedAged, 80 and overDemographyHumansMiddle AgedMorpholinesOndansetronPostoperative CarePostoperative Nausea and VomitingRetrospective StudiesRisk FactorsYoung AdultfosaprepitantMorpholinesOndansetron

Identifiers

PMID29410964
PMCPMC5749222
OpenAlexW2777186054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.